TY  - JOUR
AU  - Capdevila, Jaume
AU  - Trigo, José Manuel
AU  - Aller, Javier
AU  - Manzano, José Luís
AU  - Adrián, Silvia García
AU  - Llopis, Carles Zafón
AU  - Reig, Òscar
AU  - Bohn, Uriel
AU  - Cajal, Teresa Ramón Y
AU  - Duran-Poveda, Manuel
AU  - Astorga, Beatriz González
AU  - López-Alfonso, Ana
AU  - Martínez, Javier Medina
AU  - Porras, Ignacio
AU  - Reina, Juan Jose
AU  - Palacios, Nuria
AU  - Grande, Enrique
AU  - Cillán, Elena
AU  - Matos, Ignacio
AU  - Grau, Juan Jose
PY  - 2017
DO  - 10.1530/EJE-17-0243
UR  - http://hdl.handle.net/10668/11384
T2  - European journal of endocrinology
AB  - Axitinib, an antiangiogenic multikinase inhibitor (MKI), was evaluated in the compassionate use programme (CUP) in Spain (October 2012-November 2014). 47 patients with advanced radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC,...
LA  - en
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Axitinib
KW  - Carcinoma, Neuroendocrine
KW  - Female
KW  - Humans
KW  - Imidazoles
KW  - Indazoles
KW  - Iodine Radioisotopes
KW  - Longitudinal Studies
KW  - Magnetic Resonance Imaging
KW  - Male
KW  - Middle Aged
KW  - Positron Emission Tomography Computed Tomography
KW  - Protein Kinase Inhibitors
KW  - Retrospective Studies
KW  - Spain
KW  - Thyroid Neoplasms
KW  - Treatment Outcome
TI  - Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC).
TY  - research article
VL  - 177
ER  -